Physician profile
Yumin Qiu
NPI 1194750612
$1,440.64
in general payments reported to CMS, 2019-2025
17 companies · $61.61 in 2025
The $61.61 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $41.87 · 2021: $223 · 2022: $220 · 2023: $485 · 2024: $247 · 2025: $61.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $793.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $309.07 | 2023-2024 | Impella |
| Boston Scientific Corporation | $297.06 | 2021-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $201.67 | 2019-2025 | |
| Abbott Laboratories | $143.12 | 2019-2024 | Aveir |
| Janssen Pharmaceuticals, INC | $84.25 | 2021-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.18 | 2019-2022 | |
| Biotronik INC. | $55.47 | 2021-2024 | Amvia Edge |
| Medtronic, INC. | $50.04 | 2023 | Corevalve Evolut R |
| Amgen INC. | $43.83 | 2024-2025 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $43.27 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.09 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $24.61 | 2023 | Arcalyst |
| Novo Nordisk INC | $22.43 | 2024 | Rybelsus, Ozempic |
| Medtronic Vascular, INC. | $17.95 | 2019 | |
| Biosense Webster, INC. | $17.66 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $12.52 | 2022 | |
| Pfizer INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yumin Qiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.